Health care imaging analytics developer Zebra Medical Vision has announced CE (European Conformity) regulatory approval of its newest algorithm to be included in its deep learning imaging analytics platform. The algorithm, capable of detecting suspected malignant lesions in mammography scans, is the latest addition to other automated tools announced in the past as part of its artificial intelligence (AI) imaging business model. Others include algorithms that automatically detect brain bleeds, vertebral fractures, coronary artery disease, osteoporosis, and more. The company provides a state-of-the-art malignancy detection product at a reasonable price. The first version to be released supports 2D hologic devices, and Zebra Medical Vision expects to add support for additional vendors and 3D support during the course of 2019. The algorithm broadens the AI1 “All-In-One” Imaging Analytics package, which has already analyzed more than one million scans in more than five countries. “Early detection of breast cancer is a crucial component of disease prevention,” said Dr. Michael Fishman, a breast imaging radiologist at Beth Israel Deaconess Medical Center in Boston. “An accurate AI assistant can provide a significant boost to radiologists seeking to provide the best care for their patients by increasing detection and limiting false positives.” “Mammography tools have had a checkered past," said Elad Benjamin, co-founder and CEO of Zebra Medical Vision, "and we plan to usher [in] a new level of performance with this algorithm and its follow-on versions.” Zebra Medical Vision uses deep learning to develop next-generation products and services for the health care industry.